California State Board of Pharmacy sends revised compounding rules to 15‑day comment period after debate over glutathione access

The California State Board of Pharmacy on Feb. 5, 2025, voted 7‑2 to approve staff responses to comments and to release the board’s third modified text of proposed compounding regulations for an additional 15‑day public comment period.

The vote followed more than three hours of board discussion and hours of public testimony focusing largely on proposed requirements for sterile and nonsterile compounding, documentation and stability testing for so‑called bulk drug substances and patient access to compounded products such as nebulized glutathione and injectable methylcobalamin.

The board motion — made on the record by Maria Jacobs, a staff presenter, and seconded by Vice Chair Renee Barker — directs staff to publish the third modified text for 15 days, and delegates to members Maria Serpa and Barker authority to review and recommend responses to any additional comments received during that period. The motion also authorized the executive officer to make technical, non‑substantive edits. The final vote tally was 7 in favor, 2 opposed (Jeff Hughes and Nicole Thiebaud).

Why it matters: The rules would update Title 16 of the California Code of Regulations governing nonsterile and sterile compounding, hazardous drugs and radiopharmaceuticals and are intended to align state requirements with U.S. Pharmacopeia (USP) chapters and applicable federal guidance. Licensees, public commenters and board members said the changes could affect patient access to some compounded therapies and impose new testing and documentation duties on pharmacies.

What the board approved and what remains under discussion - Action taken: The board approved staff responses to comments and authorized publication of the third modified text for a 15‑day comment period for stakeholder input. Staff said the third modified text reflects changes based on public feedback and earlier board direction, and that many edits are non‑substantive (grammar/readability). Maria Jacobs presented the changes. - Key topics addressed in the draft text: reorganization and clarification of nonsterile compounding rules (e.g., labeling, SOP content), documentation and verification requirements when a compounded product is intended to produce a clinically significant difference, new language on consultation and counseling requirements, recording and reporting potential quality problems, and revisions to hazardous‑drug and radiopharmaceutical provisions. - Delegation: The board delegated to members Serpa and Barker authority to review any additional comments received during the 15‑day window and advise the board; the executive…